VANDA PHARMACEUTICALS INC

Vanda Pharmaceuticals (VNDA) Slips 0.99% to $4.01 – A Strategic Buying Opportunity in CNS Biotech

Vanda Pharmaceuticals (VNDA) dips 0.99% to $4.01 as investors eye CNS drug pipeline, attractive valuation vs peers, potential rebound to $9.94.

Samantha Roth

26/10/2026, 09:05

2 minutes to read

Vanda Pharma’s Decline: Thin Liquidity, Low Confidence and No Data

Vanda Pharmaceuticals’ stock dives—$4.05 vs. a $6.32 200‑day SMA—highlighting thin liquidity, opaque reporting, and a steep 19.6% decline, warning investors of hidden risk.

Vanessa Liu

23/10/2026, 13:07

3 minutes to read

Vanda Pharmaceuticals (VNDA) Shares Fall 3.84% as Q3 Results Await – Market Update

Explore Vanda Pharmaceuticals’ Q3 2026 earnings, market trends, and CNS drug pipeline insights. Get the latest price action and strategic updates.

Elliot Mercer

22/10/2026, 17:53

2 minutes to read

Vanda Pharmaceuticals Surges 1.96% as 200‑Day SMA Signals Potential Rebound in CNS Drug Pipeline

Vanda Pharmaceuticals (VNDA) sees a modest 1.96% rebound amid a tough sector, with Phase II CNS pipeline progress hinting at future upside.

Samantha Roth

22/10/2026, 04:40

2 minutes to read